Influencing factors of intracranial hemorrhage induced by intravenous Alteplase thrombolytic therapy in patients with acute cerebral infarction
YUAN Qihong1 XIN Yue2 LIU Yue1 ZHANG Chunmei1
1.The Second Department of Neurology,the First Affiliated Hospital of Qiqihar Medical College,Heilongjiang Province,Qiqihar 161041,China;
2.Department of Rehabilitation,the First Affiliated Hospital of Qiqihar Medical College,Heilongjiang Province,Qiqihar 161041,China
Abstract：Objective To investigate the influential factors of intracranial hemorrhage (ICH) induced by Alteplase intravenous thrombolytic therapy in patients with acute cerebral infarction.Methods A retrospective analysis was performed on 44 cases of acute cerebral infarction treated with intravenous thrombolysis in the First Affiliated Hospital of Qiqihar Medical College from January 2021 to November 2022.Relevant clinical data of patients were collected.According to the presence or absence of ICH after intravenous thrombolytic therapy with Alteplase,patients were divided into ICH group and ICH free group,and the influencing factors of ICH after thrombolytic therapy were analyzed.Results Among the 44 patients,14 had ICH after intravenous thrombolytic therapy with Alteplase (31.8%).Gender,age,smoking,alcohol consumption,diabetes,past antithrombotic drugs,onset-to-needle time (ONT),TOAST classification,National Institutes of Health stroke scale (NIHSS) score before thrombolysis,baseline blood glucose level,incidence of elevated low-density lipoprotein cholesterol,and incidence of hyperhomocysteine were compared between patients in the ICH and non-ICH groups,and there were no statistical significances (P＞0.05).There were significant differences in the incidence of hypertension and previous ischemic stroke between the two groups (P＜0.05).Multivariate logistic regression analysis showed that age,ONT and history of ischemic stroke were independent influencing factors for ICH after Alteplase thrombolysis (P ＜0.05).Conclusion The use of Alteplase in acute cerebral infarction patients with ICH is related to age,hypertension,ONT,ischemic stroke history and many factors,clinical attention should be paid to patients with these risk factors,timely intervention.
Berge E，Whiteley W，Audebert H，et al.European Stroke Organisation（ESO）guidelines on intravenous thrombolysis for acute ischaemic stroke[J].Eur Stroke J，2021，6（1）：Ⅰ-LⅫ.
[2]
Lorenzano S，Vestri A，Lancia U，et al.Thrombolysis in elderly stroke patients in Italy（TESPI）trial and updated meta-analysis of randomized controlled trials[J].Int J Stroke，2021，16（1）：43-54.
Li L，Han Z，Yang Z，et al.Circulating inflammatory biomarkers level before thrombolysis for acute ischemic stroke predicts symptomatic intracerebral hemorrhage[J].Aging Dis，2023，14（1）：9-13.
[5]
Bernardo-Castro S，Sousa JA，Brás A，et al.Pathophysiology of blood-brain barrier permeability throughout the different stages of ischemic stroke and its implication on hemorrhagic transformation and recovery[J].Front Neurol，2020，11：594672.
[6]
Kase CS，Furlan AJ，Wechsler LR，et al.Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke：the PROACT Ⅱtrial[J].Neurology，2001，57（9）：1603-1610.
[7]
Larrue V，von Kummer R，Müller A，et al.Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator.A secondary analysis of the European-Australasian Acute Stroke Study（ECASS Ⅱ）[J].Stroke，2001，32（2）：438-441.
[8]
Wahlgren N，Ahmed N，Dávalos A，et al.Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study（SITS-MOST）：An observational study[J].Lancet，2007，369（9558）：275-282.
Goldstein LB，Jones MR，Matchar DB，et al.Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment（TOAST）criteria[J].Stroke，2001，32（5）：1091-1098.
[11]
Heldner MR，Zubler C，Mattle HP，et al.National Institutes of Health stroke scale score and vessel occlusion in 2152 patients with acute ischemic stroke[J].Stroke，2013，44（4）：1153-1157.
[12]
Kvistad CE，Naess H，Helleberg BH，et al.Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway（NOR-TEST 2，part A）：a phase 3，randomised，open-label，blinded endpoint，non-inferiority trial[J].Lancet Neurol，2022，21（6）：511-519.
[13]
Soni M，Wijeratne T，Ackland DC.A risk score for prediction of symptomatic intracerebral haemorrhage following thrombolysis[J].Int J Med Inform，2021，156：104586.
[14]
Niu P，Li L，Zhang Y，et al.Immune regulation based on sex differences in ischemic stroke pathology[J].Front Immunol，2023，14：1087815.
Lei YS，Li H，Lei JY，et al.Effect of intravenous thrombolysis in acute ischemic stroke patients with cerebral microbleeds and analysis of risk factors for hemorrhagic transformation[J].Eur Rev Med Pharmacol Sci，2022，26（3）：779-786.
[17]
Mair G，Alzahrani A，Lindley RI，et al.Feasibility and diagnostic accuracy of using brain attenuation changes on CT to estimatetimeofischemicstrokeonset[J].Neuroradiology，2021，63（6）：869-878.
[18]
Kleindorfer DO，Towfighi A，Chaturvedi S，et al.2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack：a guideline from the American Heart Association/American Stroke Association[J].Stroke，2021，52（7）：e364-e467.
Shah S，Liang L，Kosinski A，et al.Safety and outcomes of intravenous tPA in acute ischemic stroke patients with prior stroke within 3 months：findings from get with the guidelines-stroke[J].Circ Cardiovasc Qual Outcomes，2020，13（1）：e006031.
[21]
Xiaoxi Z，Xuan Z，Lei Z，et al.Baseline blood pressure does not modify the effect of intravenous thrombolysis in successfully revascularized patients[J].Front Neurol，2022，13：984599.
[22]
Karaszewski B，Gójska-Grymajlo A，Czaplewska P，et al.SWATH-MS for prospective identification of protein blood biomarkers of rtPA-associated intracranial hemorrhage in acute ischemic stroke：a pilot study[J].Sci Rep，2021，11（1）：18765.
[23]
D'Anna L，Filippidis FT，Harvey K，et al.Extent of white matter lesion is associated with early hemorrhagic transformation in acute ischemic stroke related to atrial fibrillation[J].Brain Behav，2021，11（8）：e2250.
[24]
Sui Y，Luo J，Dong C，et al.Implementation of regional Acute Stroke Care Map increases thrombolysis rates for acute ischaemic stroke in Chinese urban area in only 3 months[J].Stroke Vasc Neurol，2021，6（1）：87-94.
[25]
Fekete KE，Héja M，Márton S，et al.Predictors and long-term outcome of intracranial hemorrhage after thrombolytic therapy foracuteischemicstroke-Aprospectivesingle-centerstudy[J].Front Neurol，2023，14：1080046.
[26]
Chen J，Li H，Lei H，et al.Determinants for a low dose of alteplase and its relationship to a lower intracerebral bleeding risk in acute ischemic stroke[J].Int J Med Sci，2022，19（12）：1762-1769.
[27]
Wang R，Zhu Y，Liu Z，et al.Neutrophil extracellular traps promote tPA-induced brain hemorrhage via cGAS in mice with stroke[J].Blood，2021，138（1）：91-103.
京公网安备 11010502046607号